184163-56-2

Basic information

• Product Name: 4-Cyano-2-(trifluoromethyl)phenylhydrazine
• Synonyms: 4-Hydrazino-3-(trifluoromethyl)benzonitrile;4-Hydrazinyl-3-(trifluoromethyl)benzonitrile
• CAS NO: 184163-56-2
• Molecular Formula: C8H6F3N3
• Molecular Weight: 201.15
• Mol File: 184163-56-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-Cyano-2-(trifluoromethyl)phenylhydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-2-(trifluoromethyl)phenylhydrazine(184163-56-2)
• EPA Substance Registry System: 4-Cyano-2-(trifluoromethyl)phenylhydrazine(184163-56-2)

Safety Data

• Hazardous Substances Data: 184163-56-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Cyano-2-(trifluoromethyl)phenylhydrazine is utilized as a reagent in organic synthesis for the preparation of a diverse range of pharmaceuticals. Its unique structure contributes to the development of new molecules with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Cyano-2-(trifluoromethyl)phenylhydrazine is employed as a key intermediate in the synthesis of compounds designed to protect crops from pests and diseases, leveraging its reactivity to form new agrochemical entities.
Used in Pharmaceutical Research:
4-Cyano-2-(trifluoromethyl)phenylhydrazine is used as a precursor in the research and development of new pharmaceuticals, particularly those with antitumor and antiviral properties. Its potential biological activity makes it a valuable compound in the quest for novel treatments.
Used in Safety and Handling Protocols:
Due to its irritant nature, 4-Cyano-2-(trifluoromethyl)phenylhydrazine is also used as a case study in the development of safety protocols and handling guidelines for chemists and researchers to ensure safe laboratory practices when working with potentially hazardous substances.

Upstream product

• 327-74-2 4-cyano-2-trifluoromethylaniline 
• 67515-59-7 4-Fluoro-3-(trifluoromethyl)benzonitrile 

Relevant articles and documents

Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer

Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase (AURKA). Therefore, dual-inhibition of N-Myc and AURKA would be an attractive therapeutic avenue for NEPC. Following our computer-aided drug discovery approach, compounds exhibiting potent N-Myc specific inhibition and strong anti-proliferative activity against several N-Myc driven cell lines, were identified. Thereafter, we have developed dual inhibitors of N-Myc and AURKA through structure-based drug design approach by merging our novel N-Myc specific chemical scaffolds with fragments of known AURKA inhibitors. Favorable binding modes of the designed compounds to both N-Myc and AURKA target sites have been predicted by docking. A promising lead compound, 70812, demonstrated low-micromolar potency against both N-Myc and AURKA in vitro assays and effectively suppressed NEPC cell growth.

Antithrombotic carboxylic acid amides

Carboxylic acid amides of formula having antithrombotic activity and a factor Xa-inhibiting activity. Exemplary are: 2-(5-amidino-2-hydroxy-phenyl)-N-[3-methyl-4-(2-tert-butoxycarbonylaminomethyl -benzimidazol-1-yl)-phenyl]-acetamide; 2-(5-amidino-2-hydro